Author: Li, Chunfeng; Cheng, Genhong
Title: Will Hydroxychloroquine Still Be a Game-Changer for COVID-19 by Combining Azithromycin? Cord-id: dq8ib0h7 Document date: 2020_8_7
ID: dq8ib0h7
Snippet: Recent small-scale clinical trials have shown promising results in the use of hydroxychloroquine, an FDA approved anti-malaria drug, for the treatment of COVID-19. However, large scale, randomized and double-blind clinical trials are needed to confirm the safety and efficacy of hydroxychloroquine in COVID-19 patients. Here, we review the progress of using hydroxychloroquine or chloroquine as anti-viral agents, failed clinical trials of chloroquine in treatment of dengue virus and influenza infec
Document: Recent small-scale clinical trials have shown promising results in the use of hydroxychloroquine, an FDA approved anti-malaria drug, for the treatment of COVID-19. However, large scale, randomized and double-blind clinical trials are needed to confirm the safety and efficacy of hydroxychloroquine in COVID-19 patients. Here, we review the progress of using hydroxychloroquine or chloroquine as anti-viral agents, failed clinical trials of chloroquine in treatment of dengue virus and influenza infection, and especially the mechanism of azithromycin in inhibiting viral replication, so as to shed light on the ongoing clinical trials and further researches of hydroxychloroquine on SARS-CoV-2 infected patients.
Search related documents:
Co phrase search for related documents- acceptable safety profile and acute respiratory: 1, 2, 3, 4, 5, 6, 7, 8
- acceptable safety profile and low income: 1
- acute infectious disease and low income: 1, 2
- acute respiratory and additional advantage: 1
- acute respiratory and long period: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
- acute respiratory and low income: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
- acute respiratory and low income population: 1, 2, 3, 4, 5
- acute respiratory and low income population affordable: 1
- acute respiratory and lysosomal enzyme: 1, 2
- acute respiratory and macrolide antibiotic: 1, 2, 3, 4
- acute respiratory distress syndrome and additional advantage: 1
- acute respiratory distress syndrome and long period: 1, 2, 3, 4, 5, 6
- acute respiratory distress syndrome and low income: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14
- acute respiratory distress syndrome and macrolide antibiotic: 1
- acute respiratory distress syndrome ards and long period: 1, 2
- acute respiratory distress syndrome ards and low income: 1, 2, 3, 4, 5, 6, 7, 8
- long period and low income: 1, 2, 3
Co phrase search for related documents, hyperlinks ordered by date